Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:bile acid conjugate
go back to main search page
Accession:CHEBI:36249 term browser browse the term
Definition:A glycine or taurine amide of a bile acid.
Synonyms:related_synonym: bile acid conjugates


show annotations for term's descendants           Sort by:
 
glycochenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA CTD PMID:32152650 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
JBrowse link
G Agt angiotensinogen multiple interactions
decreases response to substance
EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]] CTD PMID:23300732 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions EXP AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid] CTD PMID:23300732 NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 5:135,482,068...135,498,693
Ensembl chr 5:135,482,068...135,498,822
JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 5:157,759,448...157,768,473
Ensembl chr 5:157,759,416...157,768,471
JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
JBrowse link
G Atg5 autophagy related 5 multiple interactions
decreases expression
ISO TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA]
Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA; Glycochenodeoxycholic Acid results in decreased expression of ATG5 protein
CTD PMID:32439580 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
JBrowse link
G Atp6v0d1 ATPase H+ transporting V0 subunit D1 decreases expression ISO Glycochenodeoxycholic Acid results in decreased expression of ATP6V0D1 mRNA CTD PMID:32439580 NCBI chr19:37,481,782...37,525,762
Ensembl chr19:37,481,782...37,525,762
JBrowse link
G Atp6v1e1 ATPase H+ transporting V1 subunit E1 decreases expression ISO Glycochenodeoxycholic Acid results in decreased expression of ATP6V1E1 mRNA CTD PMID:32439580 NCBI chr 4:153,351,434...153,373,558
Ensembl chr 4:153,351,421...153,373,649
JBrowse link
G Bcl2a1 BCL2-related protein A1 increases expression EXP Glycochenodeoxycholic Acid results in increased expression of BCL2A1 mRNA CTD PMID:15767249 NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
JBrowse link
G Bcl2l13 BCL2 like 13 decreases expression ISO Glycochenodeoxycholic Acid results in decreased expression of BCL2L13 protein CTD PMID:32439580 NCBI chr 4:153,385,200...153,438,096
Ensembl chr 4:153,385,205...153,436,660
JBrowse link
G Becn1 beclin 1 multiple interactions
decreases expression
ISO TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA]
Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA; Glycochenodeoxycholic Acid results in decreased expression of BECN1 protein
CTD PMID:32439580 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression EXP Glycochenodeoxycholic Acid results in increased expression of BIRC5 mRNA CTD PMID:15767249 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
increases activity
ISO
EXP
Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Egtazic Acid promotes the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Nitric Oxide inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in increased cleavage of CASP3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]
CTD PMID:12873810, PMID:15767249, PMID:16322111, PMID:19837105, PMID:20020783, PMID:23300732, PMID:25125499 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 increases activity
increases cleavage
EXP
ISO
Glycochenodeoxycholic Acid results in increased activity of CASP8 protein
Glycochenodeoxycholic Acid results in increased cleavage of CASP8 protein
CTD PMID:12873810, PMID:15767249, PMID:25125499 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 increases activity
multiple interactions
EXP
ISO
Glycochenodeoxycholic Acid results in increased activity of CASP9 protein
Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP9 protein]
CTD PMID:15767249, PMID:16322111 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr11:33,813,041...33,815,418
Ensembl chr11:33,845,463...33,847,793
JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions
increases expression
ISO Glycochenodeoxycholic Acid results in decreased expression of and results in increased phosphorylation of CFLAR protein
Glycochenodeoxycholic Acid results in increased expression of CFLAR protein
Glycochenodeoxycholic Acid promotes the reaction [lysophosphatidylethanolamine analog results in increased expression of CFLAR protein]; lysophosphatidylethanolamine analog promotes the reaction [Glycochenodeoxycholic Acid results in increased expression of CFLAR protein]
CTD PMID:25125499 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Csf1 colony stimulating factor 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
JBrowse link
G Cycs cytochrome c, somatic affects localization EXP Glycochenodeoxycholic Acid affects the localization of CYCS protein CTD PMID:15767249 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr19:19,264,984...19,323,817
Ensembl chr19:19,265,164...19,315,357
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
EXP
ISO
AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA
CTD PMID:23300732, PMID:32152650 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr11:81,741,342...81,757,806
Ensembl chr11:81,741,297...81,757,813
JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 6:64,165,913...64,170,122
Ensembl chr 6:64,165,913...64,170,151
JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr17:84,986,994...85,141,464
Ensembl chr17:84,986,991...85,141,210
JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 3:67,538,289...67,578,308
Ensembl chr 3:67,538,289...67,578,306
JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 5:160,325,088...160,352,874
Ensembl chr 5:160,325,107...160,352,927
JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr18:28,466,892...28,501,013
Ensembl chr18:28,466,311...28,495,937
JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 2:120,503,093...120,531,782
Ensembl chr 2:120,504,130...120,531,782
JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 2:60,419,446...60,446,656
Ensembl chr 2:60,419,525...60,446,510
JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr15:104,186,918...104,226,236
Ensembl chr15:104,186,792...104,226,329
JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 5:120,330,372...120,492,515
Ensembl chr 5:120,340,646...120,492,487
JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr15:4,356,512...4,360,788
Ensembl chr15:4,356,261...4,360,564
JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 2:28,049,217...28,061,023
Ensembl chr 2:28,049,217...28,061,029
JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions EXP
ISO
Glycochenodeoxycholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Glycochenodeoxycholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA
CTD PMID:3783048, PMID:32152650 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Gsta3 glutathione S-transferase alpha 3 multiple interactions EXP Glycochenodeoxycholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein] CTD PMID:3783048 NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 4:71,621,777...71,626,096
Ensembl chr 4:71,621,729...71,626,107
JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
JBrowse link
G Gstm4 glutathione S-transferase mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 2:210,834,013...210,839,242
Ensembl chr 2:210,833,884...210,839,295
JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO Glycochenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance ISO HSD11B1 gene mutant form results in decreased abundance of Glycochenodeoxycholic Acid CTD PMID:25061560 NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:45,905,371...45,920,014
Ensembl chr12:45,905,371...45,920,013
JBrowse link
G Huwe1 HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1 multiple interactions ISO Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein] CTD PMID:21507240 NCBI chr  X:21,474,627...21,603,348
Ensembl chr  X:21,499,934...21,598,876
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr16:20,485,028...20,486,707
Ensembl chr16:20,485,029...20,486,707
JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr19:48,179,826...48,200,995
Ensembl chr19:48,194,804...48,196,748
JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr 7:120,580,743...120,592,095
Ensembl chr 7:120,580,743...120,592,095
JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr10:109,802,877...109,811,476
Ensembl chr10:109,806,159...109,811,323
JBrowse link
G Mafk MAF bZIP transcription factor K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr12:16,923,989...16,934,706
Ensembl chr12:16,923,990...16,934,706
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions
decreases expression
ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of MAP1LC3B mRNA] CTD PMID:32152650, PMID:32439580 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases activity
multiple interactions
ISO
EXP
Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein
[AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein]
CTD PMID:21507240, PMID:23300732 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases activity
multiple interactions
ISO
EXP
Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein
[AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein]
CTD PMID:21507240, PMID:23300732 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mapkapk3 MAPK activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 8:116,012,126...116,046,012
Ensembl chr 8:116,012,121...116,045,954
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
increases phosphorylation
ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein]; [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein] which results in decreased degradation of MCL1 protein; Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein]
Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein; lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein]
CTD PMID:21507240, PMID:25125499 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 2:140,708,396...140,727,381
Ensembl chr 2:140,708,397...140,727,281
JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr19:43,508,416...43,535,050
Ensembl chr19:43,506,976...43,528,851
JBrowse link
G Nos2 nitric oxide synthase 2 increases expression EXP Glycochenodeoxycholic Acid results in increased expression of NOS2 mRNA CTD PMID:15767249 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nos3 nitric oxide synthase 3 decreases expression
multiple interactions
ISO Glycochenodeoxycholic Acid results in decreased expression of NOS3; Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA; Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein
[Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein] which results in decreased abundance of Nitric Oxide; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3]
CTD PMID:19837105, PMID:20020783 NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr17:32,131,847...32,158,559
Ensembl chr17:32,132,347...32,158,538
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA CTD PMID:32152650 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage ISO Glycochenodeoxycholic Acid results in increased cleavage of PARP1 protein CTD PMID:25125499 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr13:49,848,939...49,909,404
Ensembl chr13:49,850,189...49,911,202
JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr 4:173,732,196...174,102,502
Ensembl chr 4:173,732,248...174,102,496
JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:22,964,121...23,047,896
Ensembl chr18:22,964,210...23,047,895
JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
JBrowse link
G Rala RAS like proto-oncogene A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr17:49,676,073...49,729,133
Ensembl chr17:49,714,294...49,727,664
JBrowse link
G Rap1a RAP1A, member of RAS oncogene family multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 2:208,193,950...208,215,186
Ensembl chr 2:208,193,954...208,215,187
JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr17:31,537,580...31,569,904
Ensembl chr17:31,537,591...31,569,904
JBrowse link
G Rras2 RAS related 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 1:178,940,515...179,010,257
Ensembl chr 1:178,940,516...179,010,257
JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Sh3glb1 SH3 domain -containing GRB2-like endophilin B1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 2:250,709,812...250,744,216
Ensembl chr 2:250,709,439...250,744,196
JBrowse link
G Slc10a1 solute carrier family 10 member 1 increases uptake
multiple interactions
ISO SLC10A1 protein results in increased uptake of Glycochenodeoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
CTD PMID:29024779, PMID:32152650 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
G Slc51a solute carrier family 51 subunit alpha multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid] CTD PMID:32152650, PMID:32294204 NCBI chr11:71,533,078...71,547,476
Ensembl chr11:71,533,078...71,547,476
JBrowse link
G Slc51b solute carrier family 51 subunit beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid] CTD PMID:32152650, PMID:32294204 NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA CTD PMID:32152650 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr 1:222,274,133...222,293,139
Ensembl chr 1:222,274,133...222,293,148
JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
JBrowse link
G Tfe3 transcription factor binding to IGHM enhancer 3 multiple interactions
decreases expression
ISO Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of TFE3 mRNA]; Glycochenodeoxycholic Acid results in decreased expression of and results in decreased activity of TFE3 protein; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA]; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA]; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of MAP1LC3B mRNA] CTD PMID:32439580 NCBI chr  X:15,574,579...15,587,826
Ensembl chr  X:15,575,934...15,587,419
JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr14:44,289,247...44,348,691
Ensembl chr14:44,289,247...44,348,691
JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:1,178,785...1,216,573
Ensembl chr18:1,178,787...1,216,409
JBrowse link
G Vcp valosin-containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 5:58,426,548...58,445,953
Ensembl chr 5:58,426,549...58,445,953
JBrowse link
glycocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 affects transport
multiple interactions
ISO ABCB11 protein affects the transport of Glycocholic Acid
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA
CTD PMID:15791618, PMID:32152650 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO Glycocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 5:135,482,068...135,498,693
Ensembl chr 5:135,482,068...135,498,822
JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 5:157,759,448...157,768,473
Ensembl chr 5:157,759,416...157,768,471
JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr11:33,813,041...33,815,418
Ensembl chr11:33,845,463...33,847,793
JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650
G Csf1 colony stimulating factor 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr19:19,264,984...19,323,817
Ensembl chr19:19,265,164...19,315,357
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr11:81,741,342...81,757,806
Ensembl chr11:81,741,297...81,757,813
JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 6:64,165,913...64,170,122
Ensembl chr 6:64,165,913...64,170,151
JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr17:84,986,994...85,141,464
Ensembl chr17:84,986,991...85,141,210
JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 3:67,538,289...67,578,308
Ensembl chr 3:67,538,289...67,578,306
JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 5:160,325,088...160,352,874
Ensembl chr 5:160,325,107...160,352,927
JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr18:28,466,892...28,501,013
Ensembl chr18:28,466,311...28,495,937
JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 2:120,503,093...120,531,782
Ensembl chr 2:120,504,130...120,531,782
JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 2:60,419,446...60,446,656
Ensembl chr 2:60,419,525...60,446,510
JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr15:104,186,918...104,226,236
Ensembl chr15:104,186,792...104,226,329
JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 5:120,330,372...120,492,515
Ensembl chr 5:120,340,646...120,492,487
JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr15:4,356,512...4,360,788
Ensembl chr15:4,356,261...4,360,564
JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 2:28,049,217...28,061,023
Ensembl chr 2:28,049,217...28,061,029
JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 4:71,621,777...71,626,096
Ensembl chr 4:71,621,729...71,626,107
JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
JBrowse link
G Gstm4 glutathione S-transferase mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 2:210,834,013...210,839,242
Ensembl chr 2:210,833,884...210,839,295
JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:45,905,371...45,920,014
Ensembl chr12:45,905,371...45,920,013
JBrowse link
G Il10 interleukin 10 decreases abundance ISO IL10 gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:27580383 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr16:20,485,028...20,486,707
Ensembl chr16:20,485,029...20,486,707
JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr19:48,179,826...48,200,995
Ensembl chr19:48,194,804...48,196,748
JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr 7:120,580,743...120,592,095
Ensembl chr 7:120,580,743...120,592,095
JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr10:109,802,877...109,811,476
Ensembl chr10:109,806,159...109,811,323
JBrowse link
G Mafk MAF bZIP transcription factor K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr12:16,923,989...16,934,706
Ensembl chr12:16,923,990...16,934,706
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mapkapk3 MAPK activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 8:116,012,126...116,046,012
Ensembl chr 8:116,012,121...116,045,954
JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 2:140,708,396...140,727,381
Ensembl chr 2:140,708,397...140,727,281
JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr19:43,508,416...43,535,050
Ensembl chr19:43,506,976...43,528,851
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr17:32,131,847...32,158,559
Ensembl chr17:32,132,347...32,158,538
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity
multiple interactions
ISO Glycocholic Acid results in increased activity of NR1H4 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA
CTD PMID:17567710, PMID:32152650 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr13:49,848,939...49,909,404
Ensembl chr13:49,850,189...49,911,202
JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr 4:173,732,196...174,102,502
Ensembl chr 4:173,732,248...174,102,496
JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:22,964,121...23,047,896
Ensembl chr18:22,964,210...23,047,895
JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
JBrowse link
G Por cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:25034404 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Rala RAS like proto-oncogene A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr17:49,676,073...49,729,133
Ensembl chr17:49,714,294...49,727,664
JBrowse link
G Rap1a RAP1A, member of RAS oncogene family multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 2:208,193,950...208,215,186
Ensembl chr 2:208,193,954...208,215,187
JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr17:31,537,580...31,569,904
Ensembl chr17:31,537,591...31,569,904
JBrowse link
G Rras2 RAS related 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 1:178,940,515...179,010,257
Ensembl chr 1:178,940,516...179,010,257
JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Sh3glb1 SH3 domain -containing GRB2-like endophilin B1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 2:250,709,812...250,744,216
Ensembl chr 2:250,709,439...250,744,196
JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA CTD PMID:32152650 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
G Slc51a solute carrier family 51 subunit alpha multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650, PMID:32294204 NCBI chr11:71,533,078...71,547,476
Ensembl chr11:71,533,078...71,547,476
JBrowse link
G Slc51b solute carrier family 51 subunit beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650, PMID:32294204 NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] CTD PMID:22316666, PMID:32152650 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr 1:222,274,133...222,293,139
Ensembl chr 1:222,274,133...222,293,148
JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr14:44,289,247...44,348,691
Ensembl chr14:44,289,247...44,348,691
JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:1,178,785...1,216,573
Ensembl chr18:1,178,787...1,216,409
JBrowse link
G Vcp valosin-containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 5:58,426,548...58,445,953
Ensembl chr 5:58,426,549...58,445,953
JBrowse link
glycodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions ISO [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA CTD PMID:32152650 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO Glycodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 multiple interactions ISO [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
JBrowse link
G Akr1a1 aldo-keto reductase family 1 member A1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 5:135,482,068...135,498,693
Ensembl chr 5:135,482,068...135,498,822
JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 5:157,759,448...157,768,473
Ensembl chr 5:157,759,416...157,768,471
JBrowse link
G Akr7a3 aldo-keto reductase family 7 member A3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
JBrowse link
G Aox1 aldehyde oxidase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
JBrowse link
G Casp3 caspase 3 multiple interactions EXP [Glycodeoxycholic Acid co-treated with Ceruletide] results in decreased activity of CASP3 protein CTD PMID:18832452 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cbr1 carbonyl reductase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr11:33,813,041...33,815,418
Ensembl chr11:33,845,463...33,847,793
JBrowse link
G Ccr2 C-C motif chemokine receptor 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650
G Csf1 colony stimulating factor 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
JBrowse link
G Cyld CYLD lysine 63 deubiquitinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr19:19,264,984...19,323,817
Ensembl chr19:19,265,164...19,315,357
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
JBrowse link
G Dnajb11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr11:81,741,342...81,757,806
Ensembl chr11:81,741,297...81,757,813
JBrowse link
G Dnajb6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
JBrowse link
G Dnajb9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 6:64,165,913...64,170,122
Ensembl chr 6:64,165,913...64,170,151
JBrowse link
G Dnajc1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr17:84,986,994...85,141,464
Ensembl chr17:84,986,991...85,141,210
JBrowse link
G Dnajc10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 3:67,538,289...67,578,308
Ensembl chr 3:67,538,289...67,578,306
JBrowse link
G Dnajc16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 5:160,325,088...160,352,874
Ensembl chr 5:160,325,107...160,352,927
JBrowse link
G Dnajc18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr18:28,466,892...28,501,013
Ensembl chr18:28,466,311...28,495,937
JBrowse link
G Dnajc19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 2:120,503,093...120,531,782
Ensembl chr 2:120,504,130...120,531,782
JBrowse link
G Dnajc21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 2:60,419,446...60,446,656
Ensembl chr 2:60,419,525...60,446,510
JBrowse link
G Dnajc3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr15:104,186,918...104,226,236
Ensembl chr15:104,186,792...104,226,329
JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 5:120,330,372...120,492,515
Ensembl chr 5:120,340,646...120,492,487
JBrowse link
G Dnajc9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr15:4,356,512...4,360,788
Ensembl chr15:4,356,261...4,360,564
JBrowse link
G Enc1 ectodermal-neural cortex 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 2:28,049,217...28,061,023
Ensembl chr 2:28,049,217...28,061,029
JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
JBrowse link
G Gpx2 glutathione peroxidase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Gstk1 glutathione S-transferase kappa 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 4:71,621,777...71,626,096
Ensembl chr 4:71,621,729...71,626,107
JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
JBrowse link
G Gstm2 glutathione S-transferase mu 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
JBrowse link
G Gstm4 glutathione S-transferase mu 4 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 2:210,834,013...210,839,242
Ensembl chr 2:210,833,884...210,839,295
JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr19:11,046,905...11,057,440
Ensembl chr19:11,046,909...11,057,254
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Hspb8 heat shock protein family B (small) member 8 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:45,905,371...45,920,014
Ensembl chr12:45,905,371...45,920,013
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr16:20,485,028...20,486,707
Ensembl chr16:20,485,029...20,486,707
JBrowse link
G Maf MAF bZIP transcription factor multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr19:48,179,826...48,200,995
Ensembl chr19:48,194,804...48,196,748
JBrowse link
G Maff MAF bZIP transcription factor F multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr 7:120,580,743...120,592,095
Ensembl chr 7:120,580,743...120,592,095
JBrowse link
G Mafg MAF bZIP transcription factor G multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr10:109,802,877...109,811,476
Ensembl chr10:109,806,159...109,811,323
JBrowse link
G Mafk MAF bZIP transcription factor K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr12:16,923,989...16,934,706
Ensembl chr12:16,923,990...16,934,706
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mapkapk3 MAPK activated protein kinase 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 8:116,012,126...116,046,012
Ensembl chr 8:116,012,121...116,045,954
JBrowse link
G Mgst2 microsomal glutathione S-transferase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 2:140,708,396...140,727,381
Ensembl chr 2:140,708,397...140,727,281
JBrowse link
G Mlkl mixed lineage kinase domain like pseudokinase multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr19:43,508,416...43,535,050
Ensembl chr19:43,506,976...43,528,851
JBrowse link
G Myl9 myosin light chain 9 multiple interactions EXP Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein]; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein] CTD PMID:29660437 NCBI chr 3:152,857,573...152,863,961
Ensembl chr 3:152,857,592...152,863,960
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr17:32,131,847...32,158,559
Ensembl chr17:32,132,347...32,158,538
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity
multiple interactions
ISO Glycodeoxycholic Acid results in increased activity of NR1H4 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA
CTD PMID:17567710, PMID:32152650 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Pik3c2b phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr13:49,848,939...49,909,404
Ensembl chr13:49,850,189...49,911,202
JBrowse link
G Pik3c2g phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr 4:173,732,196...174,102,502
Ensembl chr 4:173,732,248...174,102,496
JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:22,964,121...23,047,896
Ensembl chr18:22,964,210...23,047,895
JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Glycodeoxycholic Acid CTD PMID:25034404 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Ppp1r12a protein phosphatase 1, regulatory subunit 12A multiple interactions EXP Glycodeoxycholic Acid inhibits the reaction [15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid results in increased phosphorylation of PPP1R12A protein] CTD PMID:29660437 NCBI chr 7:51,404,971...51,515,382
Ensembl chr 7:51,404,919...51,515,373
JBrowse link
G Rala RAS like proto-oncogene A multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr17:49,676,073...49,729,133
Ensembl chr17:49,714,294...49,727,664
JBrowse link
G Rap1a RAP1A, member of RAS oncogene family multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 2:208,193,950...208,215,186
Ensembl chr 2:208,193,954...208,215,187
JBrowse link
G Rhoa ras homolog family member A multiple interactions EXP Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein] CTD PMID:29660437 NCBI chr 8:117,082,440...117,116,244
Ensembl chr 8:117,106,576...117,116,167
JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr17:31,537,580...31,569,904
Ensembl chr17:31,537,591...31,569,904
JBrowse link
G Rras2 RAS related 2 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr 1:178,940,515...179,010,257
Ensembl chr 1:178,940,516...179,010,257
JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Sh3glb1 SH3 domain -containing GRB2-like endophilin B1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 2:250,709,812...250,744,216
Ensembl chr 2:250,709,439...250,744,196
JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA CTD PMID:32152650 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
G Slc51a solute carrier family 51 subunit alpha multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA CTD PMID:32152650 NCBI chr11:71,533,078...71,547,476
Ensembl chr11:71,533,078...71,547,476
JBrowse link
G Slc51b solute carrier family 51 subunit beta multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA CTD PMID:32152650 NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA CTD PMID:32152650 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Stip1 stress-induced phosphoprotein 1 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr 1:222,274,133...222,293,139
Ensembl chr 1:222,274,133...222,293,148
JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions ISO [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
JBrowse link
G Ube2k ubiquitin-conjugating enzyme E2K multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr14:44,289,247...44,348,691
Ensembl chr14:44,289,247...44,348,691
JBrowse link
G Usp14 ubiquitin specific peptidase 14 multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:1,178,785...1,216,573
Ensembl chr18:1,178,787...1,216,409
JBrowse link
G Vcp valosin-containing protein multiple interactions ISO [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 5:58,426,548...58,445,953
Ensembl chr 5:58,426,549...58,445,953
JBrowse link
glycolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance ISO HSD11B1 gene mutant form results in decreased abundance of glycolithocholic acid CTD PMID:25061560 NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of glycolithocholic acid CTD PMID:25034404 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
glycoursodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Edn1 endothelin 1 decreases expression ISO glycoursodeoxycholic acid results in decreased expression of EDN1 protein CTD PMID:15556138 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
JBrowse link
G Slc4a2 solute carrier family 4 member 2 multiple interactions ISO [glycoursodeoxycholic acid co-treated with Dexamethasone] results in increased expression of SLC4A2 mRNA alternative form CTD PMID:18188457 NCBI chr 4:7,264,677...7,282,355
Ensembl chr 4:7,264,683...7,281,223
JBrowse link
G Tp53 tumor protein p53 multiple interactions EXP glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
sulfoglycolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc10a1 solute carrier family 10 member 1 increases uptake ISO SLC10A1 protein results in increased uptake of sulfolithocholylglycine CTD PMID:29024779 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
tauro-beta-muricholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 increases expression
multiple interactions
EXP tauromuricholic acid results in increased expression of ABCB11 protein
tauromuricholic acid results in increased expression of and results in increased activity of ABCB11 protein
CTD PMID:11672435, PMID:12644037 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression
multiple interactions
EXP tauromuricholic acid results in increased expression of ABCC2 protein
tauromuricholic acid results in increased expression of and results in increased activity of ABCC2 protein
CTD PMID:11672435, PMID:12644037 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression EXP tauromuricholic acid results in increased expression of ABCC3 protein CTD PMID:11672435 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases secretion
increases abundance
ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin affects the secretion of tauromuricholic acid]
AHR gene mutant form results in increased secretion of tauromuricholic acid
AHR gene mutant form results in increased abundance of tauromuricholic acid
CTD PMID:29452137, PMID:32679164 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL2 mRNA CTD PMID:22098667 NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL1 mRNA CTD PMID:22098667 NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
JBrowse link
G Fech ferrochelatase affects abundance ISO FECH protein affects the abundance of tauromuricholic acid CTD PMID:29906468 NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of ICAM1 mRNA CTD PMID:22098667 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Il10 interleukin 10 increases abundance ISO IL10 gene mutant form results in increased abundance of tauromuricholic acid CTD PMID:27580383 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 affects abundance ISO NR1H4 protein affects the abundance of tauromuricholic acid CTD PMID:30556042 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions
increases abundance
ISO [PPARA gene mutant form results in increased susceptibility to Clofibrate] which results in increased abundance of tauromuricholic acid; PPARA gene mutant form inhibits the reaction [Gemfibrozil results in increased abundance of tauromuricholic acid]
PPARA gene mutant form results in increased abundance of tauromuricholic acid
CTD PMID:24385052, PMID:29175453 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Slc10a2 solute carrier family 10 member 2 increases expression EXP tauromuricholic acid results in increased expression of SLC10A2 protein CTD PMID:11672435 NCBI chr16:90,324,420...90,350,254
Ensembl chr16:90,324,361...90,345,865
JBrowse link
G Smad3 SMAD family member 3 increases abundance ISO SMAD3 protein results in increased abundance of tauromuricholic acid CTD PMID:23034213 NCBI chr 8:68,569,530...68,678,349
Ensembl chr 8:68,569,530...68,678,349
JBrowse link
taurochenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 affects transport
increases expression
ISO
EXP
ABCB11 protein affects the transport of Taurochenodeoxycholic Acid
Taurochenodeoxycholic Acid results in increased expression of ABCB11 protein
CTD PMID:11343252, PMID:11672435 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression EXP Taurochenodeoxycholic Acid results in increased expression of ABCC2 protein CTD PMID:11672435 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression EXP Taurochenodeoxycholic Acid results in increased expression of ABCC3 protein CTD PMID:11672435 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Ahr aryl hydrocarbon receptor increases secretion
increases abundance
ISO AHR gene mutant form results in increased secretion of Taurochenodeoxycholic Acid
AHR gene mutant form results in increased abundance of Taurochenodeoxycholic Acid
CTD PMID:32679164 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Fech ferrochelatase affects abundance ISO FECH protein affects the abundance of Taurochenodeoxycholic Acid CTD PMID:29906468 NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO Taurochenodeoxycholic Acid results in increased phosphorylation of and results in decreased activity of GSK3B protein CTD PMID:20512997 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO Taurochenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Il10 interleukin 10 increases abundance ISO IL10 gene mutant form results in increased abundance of Taurochenodeoxycholic Acid CTD PMID:27580383 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Taurochenodeoxycholic Acid CTD PMID:25034404 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Slc10a2 solute carrier family 10 member 2 increases expression EXP Taurochenodeoxycholic Acid results in increased expression of SLC10A2 protein CTD PMID:11672435 NCBI chr16:90,324,420...90,350,254
Ensembl chr16:90,324,361...90,345,865
JBrowse link
G Slc51a solute carrier family 51 subunit alpha multiple interactions ISO [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid] CTD PMID:32294204 NCBI chr11:71,533,078...71,547,476
Ensembl chr11:71,533,078...71,547,476
JBrowse link
G Slc51b solute carrier family 51 subunit beta multiple interactions ISO [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid] CTD PMID:32294204 NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
JBrowse link
G Smad3 SMAD family member 3 increases abundance ISO SMAD3 protein results in increased abundance of Taurochenodeoxycholic Acid CTD PMID:23034213 NCBI chr 8:68,569,530...68,678,349
Ensembl chr 8:68,569,530...68,678,349
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression EXP Taurochenodeoxycholic Acid results in increased expression of TGFB1 protein CTD PMID:8743917 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor increases expression EXP Taurochenodeoxycholic Acid results in increased expression of TNF protein CTD PMID:8743917 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
taurocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca8 ATP binding cassette subfamily A member 8 affects transport ISO ABCA8 protein affects the transport of Taurocholic Acid CTD PMID:12379217 NCBI chr10:98,236,919...98,308,288
Ensembl chr10:98,237,141...98,294,522
JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 affects import
increases uptake
increases expression
multiple interactions
increases transport
increases export
affects transport
increases import
affects secretion
decreases uptake
ISO
EXP
ABCB11 protein affects the import of Taurocholic Acid
ABCB11 protein results in increased uptake of Taurocholic Acid
Taurocholic Acid results in increased expression of ABCB11 mRNA
2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide inhibits the reaction [ABCB11 protein results in increased import of Taurocholic Acid]; 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Amiodarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Astemizole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atazanavir Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atenolol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atropine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Benzbromarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; bisbenzimide ethoxide trihydrochloride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Bosentan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Budesonide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Calcium deficiency inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; Cefaclor inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Celecoxib inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; chelerythrine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholates inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clarithromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clotrimazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cyclosporine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dehydroepiandrosterone Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diclofenac inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diethylstilbestrol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dipyridamole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Disulfiram inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; efavirenz inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Elacridar inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; ergocristine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Erythromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ezetimibe inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Felodipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fenofibrate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Floxacillin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fluvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Fluvoxamine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fusidic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; glimepiride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glipizide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glyburide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glycyrrhizic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Imatinib Mesylate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indocyanine Green inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indomethacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Isradipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ketoconazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Kynurenic Acid inhibits the reaction [ABCB11 protein results in increased uptake of Taurocholic Acid]; Lopinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Loratadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Losartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Midazolam inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Mifepristone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; morin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Naproxen inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; nefazodone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nelfinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nicardipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nifedipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrendipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrofurantoin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ofloxacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; olmesartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pilsicainide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Progesterone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ranolazine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; repaglinide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Reserpine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ritonavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosiglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosuvastatin Calcium inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Saquinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Silymarin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; simvastatin acid inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Spironolactone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfamethoxazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfinpyrazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Taurolithocholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Telmisartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Terfenadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Tinidazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; tipranavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Troglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; verlukast inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Vinblastine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
ABCB11 protein affects the transport of Taurocholic Acid
Taurocholic Acid results in increased expression of and results in increased activity of ABCB11 protein; troglitazone inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; troglitazone sulfate inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]
Taurocholic Acid results in increased expression of ABCB11 protein
ABCB11 protein affects the secretion of Taurocholic Acid
ABCB11 protein results in decreased uptake of Taurocholic Acid
ABCB11 protein affects the transport of Taurocholic Acid; ABCB11 protein mutant form affects the transport of Taurocholic Acid
CTD PMID:10617675, PMID:11113123, PMID:11179459, PMID:11557132, PMID:12518026, PMID:12642476, PMID:12644037, PMID:12865277, PMID:14672610, PMID:14724752, PMID:15465654, PMID:15791618, PMID:15901796, PMID:16039748, PMID:19223659, PMID:20147439, PMID:20829430, PMID:24014644, PMID:25862123, PMID:27160211, PMID:27676153, PMID:30639138, PMID:31348918 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A increases expression EXP
ISO
Taurocholic Acid results in increased expression of ABCB1 protein
Taurocholic Acid results in increased expression of ABCB1A mRNA
CTD PMID:11113123, PMID:27160211 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 increases expression EXP Taurocholic Acid results in increased expression of ABCB4 protein CTD PMID:11113123 NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO Taurocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases activity
increases expression
multiple interactions
EXP
ISO
Taurocholic Acid results in increased activity of ABCC2 protein; Taurocholic Acid results in increased activity of ABCC2 protein modified form
Taurocholic Acid results in increased expression of ABCC2 mRNA
Taurocholic Acid results in increased expression of and results in increased activity of ABCC2 protein
CTD PMID:12644037, PMID:15904671, PMID:27160211 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases activity
multiple interactions
increases uptake
affects transport
ISO
EXP
Taurocholic Acid results in increased activity of ABCC3 protein
4-cresylglucuronide promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid]; hippuric acid promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid]
ABCC3 protein affects the transport of Taurocholic Acid
CTD PMID:11557524, PMID:17569508, PMID:30639138 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 increases expression ISO Taurocholic Acid results in increased expression of ABCG2 mRNA CTD PMID:27160211 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases secretion
ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Taurocholic Acid]
AHR gene mutant form results in increased secretion of Taurocholic Acid
CTD PMID:29452137, PMID:32679164 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]] CTD PMID:12388182 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Apoa1 apolipoprotein A1 decreases expression ISO Taurocholic Acid results in decreased expression of APOA1 protein CTD PMID:19445040 NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
JBrowse link
G Apoa4 apolipoprotein A4 multiple interactions EXP [Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in increased expression of APOA4 protein CTD PMID:6631239 NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
JBrowse link
G Apoe apolipoprotein E multiple interactions EXP [Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in decreased expression of APOE protein CTD PMID:6631239 NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
increases expression
ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of BCL2 protein] CTD PMID:18512153 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Blvra biliverdin reductase A increases expression ISO Taurocholic Acid results in increased expression of BLVRA mRNA CTD PMID:18706437 NCBI chr 3:119,552,550...119,577,796
Ensembl chr 3:119,561,290...119,577,806
JBrowse link
G Bnip3l BCL2 interacting protein 3 like increases expression EXP Taurocholic Acid results in increased expression of BNIP3L mRNA; Taurocholic Acid results in increased expression of BNIP3L protein CTD PMID:14530762 NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
JBrowse link
G Casp3 caspase 3 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein] CTD PMID:12388182 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP8 protein] CTD PMID:12388182 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions EXP Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP9 protein] CTD PMID:12388182 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cav1 caveolin 1 increases secretion ISO CAV1 protein results in increased secretion of Taurocholic Acid CTD PMID:14647059 NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
JBrowse link
G Cav2 caveolin 2 increases secretion ISO CAV2 protein results in increased secretion of Taurocholic Acid CTD PMID:14647059 NCBI chr 4:44,573,264...44,580,640
Ensembl chr 4:44,573,264...44,580,638
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]] CTD PMID:21224055, PMID:28505368 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL20 mRNA] CTD PMID:21224055 NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression ISO Taurocholic Acid results in increased expression of CCL3 mRNA CTD PMID:21224055 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
JBrowse link
G Ccl4 C-C motif chemokine ligand 4 increases expression ISO Taurocholic Acid results in increased expression of CCL4 mRNA CTD PMID:21224055 NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 increases expression ISO Taurocholic Acid results in increased expression of CCL5 mRNA CTD PMID:21224055 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Ccl7 C-C motif chemokine ligand 7 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL7 mRNA] CTD PMID:21224055 NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]
Taurocholic Acid results in increased expression of CCND1 mRNA; Taurocholic Acid results in increased expression of CCND1 protein
CTD PMID:18512153, PMID:18840136 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccne1 cyclin E1 multiple interactions
increases expression
ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein] CTD PMID:18512153 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Cel carboxyl ester lipase multiple interactions ISO Taurocholic Acid inhibits the reaction [Polyphenols results in decreased activity of CEL protein] CTD PMID:16099206 NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
JBrowse link
G Cftr CF transmembrane conductance regulator affects uptake
increases activity
ISO CFTR protein mutant form affects the uptake of Taurocholic Acid
Taurocholic Acid results in increased activity of CFTR protein
CTD PMID:15099439, PMID:16037545 NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CSF2 mRNA] CTD PMID:21224055 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Csf3 colony stimulating factor 3 increases expression ISO Taurocholic Acid results in increased expression of CSF3 mRNA CTD PMID:21224055 NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 increases expression ISO Taurocholic Acid results in increased expression of CXCL10 mRNA CTD PMID:21224055 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 increases expression ISO Taurocholic Acid results in increased expression of CXCL11 mRNA CTD PMID:21224055 NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
JBrowse link
G Cxcl13 C-X-C motif chemokine ligand 13 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL13 mRNA] CTD PMID:21224055 NCBI chr14:15,253,146...15,258,221
Ensembl chr14:15,253,125...15,258,207
JBrowse link
G Cxcl16 C-X-C motif chemokine ligand 16 increases expression ISO Taurocholic Acid results in increased expression of CXCL16 mRNA CTD PMID:21224055 NCBI chr10:57,060,005...57,064,600
Ensembl chr10:57,060,007...57,064,600
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions
ISO Taurocholic Acid results in increased expression of CXCL2 mRNA; Taurocholic Acid results in increased expression of CXCL2 protein
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL2 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein]
CTD PMID:21224055, PMID:22098667, PMID:26176423 NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 increases expression
multiple interactions
ISO Taurocholic Acid results in increased expression of CXCL1 mRNA
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL1 mRNA; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA]
CTD PMID:21224055, PMID:22098667, PMID:26176423 NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
JBrowse link
G Cxcl6 C-X-C motif chemokine ligand 6 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL5 mRNA] CTD PMID:21224055 NCBI chr14:18,860,201...18,920,839
Ensembl chr14:18,860,264...18,862,407
JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression EXP Taurocholic Acid results in decreased expression of CYP27A1 mRNA CTD PMID:7832767 NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
JBrowse link
G Cyp2a1 cytochrome P450, family 2, subfamily a, polypeptide 1 decreases activity EXP Taurocholic Acid results in decreased activity of CYP2A1 protein CTD PMID:8889968 NCBI chr 1:83,711,223...83,725,222
Ensembl chr 1:83,653,234...83,766,484
JBrowse link
G Cyp2c11 cytochrome P450, subfamily 2, polypeptide 11 decreases activity EXP Taurocholic Acid results in decreased activity of CYP2C11 protein CTD PMID:8889968 NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity EXP Taurocholic Acid results in decreased activity of CYP3A2 protein CTD PMID:8889968 NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
decreases expression
ISO
EXP
FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA] CTD PMID:7832767, PMID:16284190 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases activity
decreases expression
EXP Taurocholic Acid results in decreased activity of CYP7B1 protein
Taurocholic Acid results in decreased expression of CYP7B1 mRNA
CTD PMID:12029625 NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
increases phosphorylation
ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein] CTD PMID:26518876 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Egr1 early growth response 1 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL20 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL13 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL5 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
Taurocholic Acid results in increased expression of EGR1 mRNA; Taurocholic Acid results in increased expression of EGR1 protein
CTD PMID:21224055 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Fech ferrochelatase affects abundance ISO FECH protein affects the abundance of Taurocholic Acid CTD PMID:29906468 NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
JBrowse link
G Fgf19 fibroblast growth factor 19 multiple interactions
increases expression
ISO [Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA
Taurocholic Acid results in increased expression of FGF15 mRNA
CTD PMID:16284190 NCBI chr 1:218,058,405...218,061,693
Ensembl chr 1:218,058,405...218,061,693
JBrowse link
G Fgfr4 fibroblast growth factor receptor 4 multiple interactions ISO FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA] CTD PMID:16284190 NCBI chr17:9,990,072...10,004,339
Ensembl chr17:9,990,078...10,004,321
JBrowse link
G Hgf hepatocyte growth factor increases uptake EXP HGF protein results in increased uptake of Taurocholic Acid CTD PMID:18031729 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hnf4a hepatocyte nuclear factor 4, alpha increases secretion ISO HNF4A protein results in increased secretion of Taurocholic Acid CTD PMID:27160211 NCBI chr 3:159,902,441...159,965,003
Ensembl chr 3:159,902,441...159,965,003
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
increases expression
EXP
ISO
rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
Taurocholic Acid results in increased expression of ICAM1 mRNA; Taurocholic Acid results in increased expression of ICAM1 protein
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of ICAM1 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
CTD PMID:19237016, PMID:21224055, PMID:22098667, PMID:26176423 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Il10 interleukin 10 increases expression
increases abundance
ISO Taurocholic Acid results in increased expression of IL10 mRNA
IL10 gene mutant form results in increased abundance of Taurocholic Acid
CTD PMID:21224055, PMID:27580383 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions
decreases import
ISO
EXP
Taurocholic Acid results in increased expression of IL1B mRNA
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid
IL1B protein results in decreased import of Taurocholic Acid
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein]
Taurocholic Acid results in increased expression of IL1B mRNA; Taurocholic Acid results in increased expression of IL1B protein
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]
CTD PMID:21224055, PMID:25604657, PMID:30876886 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 multiple interactions
decreases import
increases expression
EXP
ISO
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]
IL6 protein results in decreased import of Taurocholic Acid
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]
Taurocholic Acid results in increased expression of IL6 mRNA; Taurocholic Acid results in increased expression of IL6 protein
CTD PMID:20035747, PMID:20382593, PMID:25604657, PMID:26518876, PMID:30876886 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Kl Klotho multiple interactions ISO Taurocholic Acid inhibits the reaction [KL protein results in increased hydrolysis of Glucuronides] CTD PMID:14701853 NCBI chr12:942,974...987,206
Ensembl chr12:943,006...987,551
JBrowse link
G Klf4 Kruppel like factor 4 increases expression ISO Taurocholic Acid results in increased expression of KLF4 mRNA CTD PMID:27151938 NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression ISO Taurocholic Acid results in increased expression of MAP1LC3B protein CTD PMID:24189133 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein] CTD PMID:26518876 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein] CTD PMID:18512153, PMID:26518876 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK8 protein] CTD PMID:28505368 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK9 protein] CTD PMID:28505368 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mir488 microRNA 488 increases expression ISO Taurocholic Acid results in increased expression of MIR488 mRNA CTD PMID:28851649 NCBI chr13:76,198,593...76,198,671
Ensembl chr13:76,198,593...76,198,671
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions
increases expression
ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 protein]
Taurocholic Acid results in increased expression of MMP2 mRNA; Taurocholic Acid results in increased expression of MMP2 protein
CTD PMID:26518876 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
increases expression
ISO JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 protein]
Taurocholic Acid results in increased expression of MMP9 mRNA; Taurocholic Acid results in increased expression of MMP9 protein
CTD PMID:26518876 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mpo myeloperoxidase multiple interactions
increases activity
increases expression
EXP astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]; Edaravone inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]
Taurocholic Acid results in increased expression of MPO protein
CTD PMID:16440434, PMID:20035747, PMID:25604657 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression
multiple interactions
ISO Taurocholic Acid results in increased expression of MYC protein
[NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA
Taurocholic Acid results in increased expression of MYC mRNA
sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of MYC protein]
CTD PMID:18512153, PMID:27151938, PMID:30556042 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nanog Nanog homeobox increases expression ISO Taurocholic Acid results in increased expression of NANOG mRNA CTD PMID:27151938 NCBI chr 4:155,531,906...155,539,268
Ensembl chr 4:155,531,906...155,539,268
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases expression ISO Taurocholic Acid results in increased expression of NFE2L2 mRNA CTD PMID:27160211 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
decreases expression
EXP astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein]
Taurocholic Acid results in decreased expression of NFKBIA mRNA; Taurocholic Acid results in decreased expression of NFKBIA protein
CTD PMID:25604657 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nfkbib NFKB inhibitor beta multiple interactions
decreases expression
EXP astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein]
Taurocholic Acid results in decreased expression of NFKBIB mRNA; Taurocholic Acid results in decreased expression of NFKBIB protein
CTD PMID:25604657 NCBI chr 1:86,941,073...86,948,845
Ensembl chr 1:86,941,074...86,948,845
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression
EXP [Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; resveratrol inhibits the reaction [[Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] CTD PMID:16389574 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 increases expression ISO Taurocholic Acid results in increased expression of NR0B2 mRNA CTD PMID:18706437 NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions
affects response to substance
affects abundance
increases expression
increases export
increases activity
ISO epiallopregnanolone sulfate inhibits the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; GW 4064 promotes the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; Taurocholic Acid binds to and results in increased activity of NR1H4 protein
NR1H4 protein affects the susceptibility to Taurocholic Acid
NR1H4 protein affects the abundance of Taurocholic Acid
Taurocholic Acid results in increased expression of NR1H4 mRNA
Taurocholic Acid results in increased activity of NR1H4 protein
[NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA; [Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of SERPINE1 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK8 protein]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK9 protein]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]]
CTD PMID:16284190, PMID:17567710, PMID:18706437, PMID:19445040, PMID:22961653, PMID:27160211, PMID:28505368, PMID:30556042 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases expression ISO Taurocholic Acid results in increased expression of NR1I2 mRNA CTD PMID:18706437, PMID:27160211 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions
increases expression
ISO [1,4-bis(2-(3,5-dichloropyridyloxy))benzene binds to and affects the activity of NR1I3 protein] which results in decreased abundance of Taurocholic Acid
Taurocholic Acid results in increased expression of NR1I3 mRNA
CTD PMID:26984780, PMID:27160211 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Pnlip pancreatic lipase increases activity
multiple interactions
EXP Taurocholic Acid results in increased activity of PNLIP protein
orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein]
CTD PMID:11668201 NCBI chr 1:279,798,187...279,811,372
Ensembl chr 1:279,798,187...279,811,372
JBrowse link
G Pon1 paraoxonase 1 multiple interactions
decreases expression
ISO FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA] CTD PMID:16284190 NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
JBrowse link
G Por cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Taurocholic Acid CTD PMID:25034404 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Pou5f1 POU class 5 homeobox 1 increases expression ISO Taurocholic Acid results in increased expression of POU5F1 mRNA CTD PMID:27151938 NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha decreases abundance ISO PPARA gene mutant form results in decreased abundance of Taurocholic Acid CTD PMID:29175453 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Taurocholic Acid results in increased expression of PTGS2 mRNA
Taurocholic Acid results in increased expression of PTGS2 protein
JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; MK 2206 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]
CTD PMID:21224055, PMID:26518876 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rab7a RAB7A, member RAS oncogene family decreases expression ISO Taurocholic Acid results in decreased expression of RAB7 protein CTD PMID:24189133 NCBI chr 4:119,910,461...119,963,065
Ensembl chr 4:119,910,478...119,959,173
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
increases phosphorylation
affects localization
EXP
ISO
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein]
Taurocholic Acid results in increased phosphorylation of RELA protein
Taurocholic Acid affects the localization of RELA protein modified form
JTE 013 inhibits the reaction [Taurocholic Acid affects the localization of RELA protein modified form]
CTD PMID:25604657, PMID:26518876 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G S1pr2 sphingosine-1-phosphate receptor 2 multiple interactions ISO S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; Taurocholic Acid results in increased activity of and results in increased uptake of S1PR2 protein CTD PMID:26518876 NCBI chr 8:21,984,914...21,995,806
Ensembl chr 8:21,984,914...21,995,806
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of SERPINE1 mRNA] CTD PMID:28505368 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Slc10a1 solute carrier family 10 member 1 multiple interactions
increases expression
increases transport
increases import
increases uptake
EXP
ISO
Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid results in increased expression of SLC10A1 mRNA
4-cresol sulfate inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; [Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid; Acetamides analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Acetanilides analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Anthraquinones analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Benzenesulfonates analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; bisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; bisphenol F inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; Fusidic Acid inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Piperazines analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Sodium deficiency inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid]; Sulfobromophthalein inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased transport of daidzein metabolite]; tetrabromobisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; tetrahydrophthalamic acid analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Tobacco Smoke Pollution inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid]
CTD PMID:19464309, PMID:22641618, PMID:23850984, PMID:25106415, PMID:25319728, PMID:25862123, PMID:27160211, PMID:27450509, PMID:27676153, PMID:27989701, PMID:29024779, PMID:30639138 NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
JBrowse link
G Slc10a2 solute carrier family 10 member 2 multiple interactions
increases transport
increases uptake
EXP
ISO
Bile Acids and Salts inhibits the reaction [SLC10A2 protein results in increased uptake of Taurocholic Acid]
Chenodeoxycholic Acid inhibits the reaction [SLC10A2 protein results in increased transport of Taurocholic Acid]
CTD PMID:19464309, PMID:25466967 NCBI chr16:90,324,420...90,350,254
Ensembl chr16:90,324,361...90,345,865
JBrowse link
G Slc19a1 solute carrier family 19 member 1 multiple interactions
decreases activity
EXP Taurocholic Acid inhibits the reaction [SLC19A1 protein affects the transport of Methotrexate]
Taurocholic Acid results in decreased activity of SLC19A1 protein
CTD PMID:14612385 NCBI chr20:12,334,675...12,354,517
Ensembl chr20:12,334,676...12,352,377
JBrowse link
G Slc22a6 solute carrier family 22 member 6 multiple interactions ISO Taurocholic Acid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] CTD PMID:11602689 NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
JBrowse link
G Slc22a8 solute carrier family 22 member 8 affects transport ISO SLC22A8 protein affects the transport of Taurocholic Acid CTD PMID:11306713 NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
JBrowse link
G Slc23a1 solute carrier family 23 member 1 increases expression ISO Taurocholic Acid results in increased expression of SLC23A1 mRNA CTD PMID:18706437 NCBI chr18:28,413,910...28,428,133
Ensembl chr18:28,414,009...28,428,117
JBrowse link
G Slc23a2 solute carrier family 23 member 2 increases expression ISO Taurocholic Acid results in increased expression of SLC23A2 mRNA CTD PMID:18706437 NCBI chr 3:124,632,491...124,842,225
Ensembl chr 3:124,632,492...124,724,252
JBrowse link
G Slc51a solute carrier family 51 subunit alpha multiple interactions ISO [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] CTD PMID:32294204 NCBI chr11:71,533,078...71,547,476
Ensembl chr11:71,533,078...71,547,476
JBrowse link
G Slc51b solute carrier family 51 subunit beta multiple interactions ISO [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] CTD PMID:32294204 NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects uptake
multiple interactions
increases uptake
increases expression
affects transport
ISO
EXP
SLCO1A4 protein affects the uptake of Taurocholic Acid
Bile Acids and Salts inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid results in increased expression of SLCO1A4 mRNA
SLCO1A4 protein affects the transport of Taurocholic Acid
CTD PMID:19464309, PMID:19833843, PMID:21561886, PMID:27160211 NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 multiple interactions
increases expression
increases uptake
EXP
ISO
Bile Acids and Salts inhibits the reaction [SLCO1B3 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid results in increased expression of SLCO1B2 mRNA
Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR]; Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid]
CTD PMID:19464309, PMID:26134461, PMID:27160211, PMID:30639138 NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
JBrowse link
G Slco2b1 solute carrier organic anion transporter family, member 2b1 multiple interactions
increases uptake
ISO Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Taurocholic Acid] CTD PMID:24285294 NCBI chr 1:164,623,313...164,671,612
Ensembl chr 1:164,623,599...164,671,577
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions
decreases expression
EXP astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein]
Taurocholic Acid results in decreased expression of SOD1 mRNA; Taurocholic Acid results in decreased expression of SOD1 protein
CTD PMID:25604657 NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases expression
decreases expression
ISO
EXP
[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]
Taurocholic Acid results in increased expression of SOD2 mRNA
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA]
CTD PMID:22316666, PMID:25604657 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sort1 sortilin 1 increases sulfation ISO SORT1 gene mutant form results in increased sulfation of Taurocholic Acid CTD PMID:28453831 NCBI chr 2:211,078,092...211,156,312
Ensembl chr 2:211,078,334...211,156,312
JBrowse link
G Sox2 SRY-box transcription factor 2 increases expression ISO Taurocholic Acid results in increased expression of SOX2 mRNA CTD PMID:27151938 NCBI chr 2:121,165,137...121,167,545
Ensembl chr 2:121,165,137...121,167,545
JBrowse link
G Sqstm1 sequestosome 1 increases expression ISO Taurocholic Acid results in increased expression of SQSTM1 protein CTD PMID:24189133 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Stat1 signal transducer and activator of transcription 1 increases phosphorylation
multiple interactions
EXP Taurocholic Acid results in increased phosphorylation of STAT1 protein
rosiglitazone inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT1 protein]
CTD PMID:19563079 NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
increases phosphorylation
ISO sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT3 protein] CTD PMID:18512153 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases import
increases expression
EXP
ISO
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Resveratrol inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]
TNF protein results in decreased import of Taurocholic Acid
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]
Taurocholic Acid results in increased expression of TNF mRNA; Taurocholic Acid results in increased expression of TNF protein
CTD PMID:16389574, PMID:19080501, PMID:19237016, PMID:19563079, PMID:20035747, PMID:20382593, PMID:25604657, PMID:26518876, PMID:30876886 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions
decreases expression
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA]
Taurocholic Acid results in decreased expression of VCAM1 protein
CTD PMID:21224055, PMID:26176423, PMID:28851649 NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
JBrowse link
taurodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions
increases abundance
ISO
EXP
[Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [Ketoconazole results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [troglitazone results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid
ABCB11 protein results in increased abundance of Taurodeoxycholic Acid
[Cyclosporine results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [troglitazone results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid
CTD PMID:14570929, PMID:20147439 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO Taurodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
increases secretion
ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Taurodeoxycholic Acid]
AHR gene mutant form results in increased secretion of Taurodeoxycholic Acid
CTD PMID:29452137, PMID:32679164 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions
ISO Taurodeoxycholic Acid results in increased activity of CASP3 protein
tauroursodeoxycholic acid inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP3 protein]
CTD PMID:12773247 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 increases activity
multiple interactions
ISO Taurodeoxycholic Acid results in increased activity of CASP9 protein
tauroursodeoxycholic acid inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP9 protein]
CTD PMID:12773247 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 increases response to substance
increases activity
ISO CHRM3 protein results in increased susceptibility to Taurodeoxycholic Acid
Taurodeoxycholic Acid results in increased activity of CHRM3 protein
CTD PMID:15964566 NCBI chr17:63,990,599...64,463,222
Ensembl chr17:63,990,599...63,994,169
JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 decreases activity
decreases expression
EXP Taurodeoxycholic Acid results in decreased activity of CYP7B1 protein
Taurodeoxycholic Acid results in decreased expression of CYP7B1 mRNA
CTD PMID:12029625 NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
JBrowse link
G Il10 interleukin 10 multiple interactions
increases abundance
ISO Taurodeoxycholic Acid promotes the reaction [irinotecan results in decreased secretion of IL10 protein]
IL10 gene mutant form results in increased abundance of Taurodeoxycholic Acid
CTD PMID:26706406, PMID:27580383 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Mapk14 mitogen activated protein kinase 14 increases activity ISO Taurodeoxycholic Acid results in increased activity of MAPK14 protein CTD PMID:14762791 NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity ISO Taurodeoxycholic Acid results in increased activity of NR1H4 protein CTD PMID:17567710 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Pnlip pancreatic lipase affects folding ISO Taurodeoxycholic Acid affects the folding of PNLIP protein CTD PMID:19346257 NCBI chr 1:279,798,187...279,811,372
Ensembl chr 1:279,798,187...279,811,372
JBrowse link
G Por cytochrome p450 oxidoreductase affects abundance ISO POR gene mutant form affects the abundance of Taurodeoxycholic Acid CTD PMID:25034404 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Stim1 stromal interaction molecule 1 multiple interactions
affects localization
EXP STIM1 protein promotes the reaction [Taurodeoxycholic Acid results in increased abundance of Calcium]
Taurodeoxycholic Acid affects the localization of STIM1 protein
CTD PMID:18342630 NCBI chr 1:167,373,894...167,533,412
Ensembl chr 1:167,373,678...167,533,420
JBrowse link
taurohyodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahr aryl hydrocarbon receptor increases secretion ISO AHR gene mutant form results in increased secretion of taurohyodeoxycholic acid CTD PMID:32679164 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
taurolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 affects localization
decreases activity
multiple interactions
EXP
ISO
Taurolithocholic Acid affects the localization of ABCB11 protein
Taurolithocholic Acid results in decreased activity of ABCB11 protein
Taurolithocholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Taurolithocholic Acid affects the localization of and affects the activity of ABCB11 protein
CTD PMID:12865277, PMID:15763547, PMID:24014644 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 affects localization
multiple interactions
EXP Taurolithocholic Acid affects the localization of ABCC2 protein
3-chloroacetylindole inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; [Colchicine co-treated with JTE 013] inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; CYM-5520 inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; Dideoxyadenosine inhibits the reaction [Taurolithocholic Acid affects the localization of ABCC2 protein]; Dideoxyadenosine inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid affects the localization of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein; Wortmannin inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]
CTD PMID:31300867 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation
multiple interactions
EXP Taurolithocholic Acid results in increased phosphorylation of AKT1 protein
JTE 013 inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]
CTD PMID:31300867 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 multiple interactions
affects binding
ISO [Taurolithocholic Acid binds to and affects the activity of CHRM3 protein] which results in increased abundance of Inositol Phosphates; Taurolithocholic Acid binds to and affects the activity of CHRM3 protein
Taurolithocholic Acid binds to CHRM3 protein
CTD PMID:12379313, PMID:12464352 NCBI chr17:63,990,599...64,463,222
Ensembl chr17:63,990,599...63,994,169
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions
ISO Taurolithocholic Acid results in increased expression of FOS mRNA
tauroursodeoxycholic acid inhibits the reaction [Taurolithocholic Acid results in increased expression of FOS mRNA]
CTD PMID:18164257 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance ISO HSD11B1 gene mutant form results in increased abundance of Taurolithocholic Acid CTD PMID:25061560 NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions
ISO Taurolithocholic Acid results in increased expression of JUN mRNA
tauroursodeoxycholic acid inhibits the reaction [Taurolithocholic Acid results in increased expression of JUN mRNA]
CTD PMID:18164257 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Por cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Taurolithocholic Acid CTD PMID:25034404 NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha increases activity
multiple interactions
EXP Taurolithocholic Acid results in increased activity of PRKACA protein
JTE 013 inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]
CTD PMID:31300867 NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
JBrowse link
G S1pr2 sphingosine-1-phosphate receptor 2 multiple interactions EXP S1PR2 protein affects the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein] CTD PMID:31300867 NCBI chr 8:21,984,914...21,995,806
Ensembl chr 8:21,984,914...21,995,806
JBrowse link
G Smad3 SMAD family member 3 increases abundance ISO SMAD3 protein results in increased abundance of Taurolithocholic Acid CTD PMID:23034213 NCBI chr 8:68,569,530...68,678,349
Ensembl chr 8:68,569,530...68,678,349
JBrowse link
taurolithocholic acid sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions
decreases response to substance
EXP AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein]
AGT protein results in decreased susceptibility to taurolithocholic acid 3-sulfate
CTD PMID:23300732 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
EXP AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein] CTD PMID:23300732 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cftr CF transmembrane conductance regulator decreases activity ISO taurolithocholic acid 3-sulfate results in decreased activity of CFTR protein CTD PMID:15634668 NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
JBrowse link
G Chrm1 cholinergic receptor, muscarinic 1 affects binding ISO taurolithocholic acid 3-sulfate binds to CHRM1 protein CTD PMID:12464352 NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
JBrowse link
G Ifng interferon gamma multiple interactions
increases expression
ISO Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IFNG mRNA] CTD PMID:22517774 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
ISO Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IL6 mRNA] CTD PMID:22517774 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
tauroursodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin decreases expression EXP tauroursodeoxycholic acid results in decreased expression of A2M mRNA CTD PMID:15885361 NCBI chr 4:154,309,426...154,359,138
Ensembl chr 4:154,309,426...154,359,137
JBrowse link
G Aadat aminoadipate aminotransferase decreases expression EXP tauroursodeoxycholic acid results in decreased expression of AADAT mRNA CTD PMID:15885361 NCBI chr16:32,832,001...32,868,680
Ensembl chr16:32,832,061...32,868,702
JBrowse link
G Aatf apoptosis antagonizing transcription factor increases expression EXP tauroursodeoxycholic acid results in increased expression of AATF mRNA CTD PMID:15885361 NCBI chr10:71,744,648...71,837,851
Ensembl chr10:71,744,659...71,837,851
JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 decreases expression
multiple interactions
increases expression
EXP tauroursodeoxycholic acid results in decreased expression of ABCB11 mRNA
tauroursodeoxycholic acid results in increased expression of and results in increased activity of ABCB11 protein
tauroursodeoxycholic acid results in increased expression of ABCB11 protein
CTD PMID:11672435, PMID:12644037, PMID:15885361 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
increases expression
EXP tauroursodeoxycholic acid results in increased expression of and results in increased activity of ABCC2 protein
tauroursodeoxycholic acid results in increased expression of ABCC2 protein
CTD PMID:11672435, PMID:12644037 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 increases expression EXP tauroursodeoxycholic acid results in increased expression of ABCC3 protein CTD PMID:11672435 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Acly ATP citrate lyase decreases expression EXP tauroursodeoxycholic acid results in decreased expression of ACLY mRNA CTD PMID:15885361 NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of ACSL1 mRNA CTD PMID:15885361 NCBI chr16:48,937,456...49,003,898
Ensembl chr16:48,937,456...49,003,246
JBrowse link
G Actn1 actinin, alpha 1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of ACTN1 mRNA CTD PMID:15885361 NCBI chr 6:103,376,557...103,470,497
Ensembl chr 6:103,375,799...103,470,555
JBrowse link
G Adh1 alcohol dehydrogenase 1 (class I) decreases expression EXP tauroursodeoxycholic acid results in decreased expression of ADH1 mRNA CTD PMID:15885361 NCBI chr 2:243,550,655...243,562,243
Ensembl chr 2:243,550,627...243,687,857
JBrowse link
G Adk adenosine kinase decreases expression EXP tauroursodeoxycholic acid results in decreased expression of ADK mRNA CTD PMID:15885361 NCBI chr15:3,033,535...3,435,888
Ensembl chr15:3,033,495...3,435,888
JBrowse link
G Agt angiotensinogen decreases expression
multiple interactions
EXP tauroursodeoxycholic acid results in decreased expression of AGT mRNA
tauroursodeoxycholic acid inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; tauroursodeoxycholic acid inhibits the reaction [AGT protein results in increased expression of FN1 protein]; tauroursodeoxycholic acid inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; tauroursodeoxycholic acid inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; tauroursodeoxycholic acid inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein]
CTD PMID:15885361, PMID:25398788 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Ahr aryl hydrocarbon receptor increases abundance
increases secretion
ISO AHR gene mutant form results in increased abundance of tauroursodeoxycholic acid
AHR gene mutant form results in increased secretion of tauroursodeoxycholic acid
CTD PMID:32679164 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Akr1b8 aldo-keto reductase family 1, member B8 increases expression EXP tauroursodeoxycholic acid results in increased expression of AKR1B8 mRNA CTD PMID:15885361 NCBI chr 4:61,772,064...61,784,637
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1d1 aldo-keto reductase family 1, member D1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of AKR1D1 mRNA CTD PMID:15885361 NCBI chr 4:65,110,706...65,143,930
Ensembl chr 4:65,110,746...65,143,941
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; tauroursodeoxycholic acid results in increased phosphorylation of and results in increased activity of AKT1 protein CTD PMID:12721362, PMID:25398788 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Amy1a amylase, alpha 1A decreases expression EXP tauroursodeoxycholic acid results in decreased expression of AMY1A mRNA CTD PMID:15885361 NCBI chr 2:216,428,709...216,443,518
Ensembl chr 2:216,428,709...216,443,518
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 affects expression
decreases expression
EXP tauroursodeoxycholic acid affects the expression of APAF1 mRNA; tauroursodeoxycholic acid affects the expression of APAF1 protein
tauroursodeoxycholic acid results in decreased expression of APAF1 mRNA
CTD PMID:15885361 NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
JBrowse link
G Apoa1 apolipoprotein A1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of APOA1 mRNA CTD PMID:15885361 NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
JBrowse link
G App amyloid beta precursor protein multiple interactions ISO
EXP
tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of BCL2 protein]; tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP2 protein]; tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP6 protein]; tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of BAX protein]; tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of TRP53 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in decreased expression of BCL2 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased activity of CASP2 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased activity of CASP6 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased expression of BAX protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased expression of TRP53 protein]
tauroursodeoxycholic acid affects the reaction [APP protein modified form affects the localization of NR3C2 protein]; tauroursodeoxycholic acid inhibits the reaction [[APP protein modified form results in increased activity of CASP3 protein] which results in increased cleavage of MAPT protein]; tauroursodeoxycholic acid inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]
CTD PMID:16728529, PMID:16923170, PMID:18368144 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Aqp8 aquaporin 8 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of AQP8 mRNA CTD PMID:15885361 NCBI chr 1:193,424,818...193,430,665
Ensembl chr 1:193,424,812...193,430,676
JBrowse link
G Arg1 arginase 1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of ARG1 mRNA CTD PMID:15885361 NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
JBrowse link
G Arl1 ADP-ribosylation factor like GTPase 1 increases expression EXP tauroursodeoxycholic acid results in increased expression of ARL1 mRNA CTD PMID:15885361 NCBI chr 7:29,282,411...29,293,455
Ensembl chr 7:29,282,305...29,293,399
JBrowse link
G As3mt arsenite methyltransferase decreases expression EXP tauroursodeoxycholic acid results in decreased expression of AS3MT mRNA CTD PMID:15885361 NCBI chr 1:266,482,787...266,514,570
Ensembl chr 1:266,482,858...266,514,569
JBrowse link
G Atf4 activating transcription factor 4 decreases expression
multiple interactions
ISO tauroursodeoxycholic acid results in decreased expression of ATF4 mRNA
tauroursodeoxycholic acid inhibits the reaction [N-palmitoylsphingosine results in increased expression of ATF4 mRNA]
tauroursodeoxycholic acid inhibits the reaction [Quercetin results in increased expression of ATF4 protein]
CTD PMID:24312631, PMID:25611565, PMID:28223344 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO
EXP
tauroursodeoxycholic acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; tauroursodeoxycholic acid inhibits the reaction [Quercetin results in increased activity of ATF6 protein]
tauroursodeoxycholic acid inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of ATF6 mRNA]; tauroursodeoxycholic acid inhibits the reaction [N-palmitoylsphingosine results in increased expression of ATF6 mRNA]
CTD PMID:20165829, PMID:25611565, PMID:28223344 NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions
increases phosphorylation
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [tauroursodeoxycholic acid results in increased phosphorylation of and results in decreased activity of BAD protein]; tauroursodeoxycholic acid results in increased phosphorylation of and results in decreased activity of BAD protein
tauroursodeoxycholic acid results in increased phosphorylation of and affects the localization of BAD protein; wortmannin inhibits the reaction [tauroursodeoxycholic acid results in increased phosphorylation of and affects the localization of BAD protein]
tauroursodeoxycholic acid results in increased phosphorylation of BAD protein
CTD PMID:12721362, PMID:15190125, PMID:17559149 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
decreases expression
increases expression
ISO
EXP
tauroursodeoxycholic acid affects the localization of and results in decreased susceptibility to BAX protein; tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of BAX protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased expression of BAX protein]
tauroursodeoxycholic acid results in decreased expression of BAX protein
tauroursodeoxycholic acid inhibits the reaction [3-nitropropionic acid affects the localization of BAX protein]; tauroursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA]
tauroursodeoxycholic acid results in increased expression of BAX protein
CTD PMID:11080188, PMID:12627974, PMID:12721362, PMID:15255934, PMID:16923170, PMID:17881359 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression
multiple interactions
EXP
ISO
tauroursodeoxycholic acid results in increased expression of BCL2 mRNA; tauroursodeoxycholic acid results in increased expression of BCL2 protein
tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in decreased expression of BCL2 mRNA]; tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein]
tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of BCL2 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in decreased expression of BCL2 protein]; tauroursodeoxycholic acid inhibits the reaction [Quercetin results in decreased expression of BCL2 protein]
CTD PMID:12721362, PMID:15255934, PMID:16923170, PMID:25611565, PMID:29751043 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of BCL2L1 mRNA CTD PMID:12721362 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G C4b complement C4B (Chido blood group) decreases expression EXP tauroursodeoxycholic acid results in decreased expression of C4B mRNA CTD PMID:15885361 NCBI chr20:4,302,344...4,316,752
Ensembl chr20:4,302,344...4,316,715
JBrowse link
G Canx calnexin multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [Tunicamycin results in increased expression of CANX protein] CTD PMID:27588471 NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861
JBrowse link
G Casp12 caspase 12 multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [Thapsigargin results in increased cleavage of CASP12 protein] CTD PMID:12198651 NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
JBrowse link
G Casp2 caspase 2 multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP2 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased activity of CASP2 protein] CTD PMID:16923170 NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
JBrowse link
G Casp3 caspase 3 multiple interactions
decreases activity
EXP
ISO
tauroursodeoxycholic acid inhibits the reaction [[APP protein modified form results in increased activity of CASP3 protein] which results in increased cleavage of MAPT protein]; tauroursodeoxycholic acid inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]; tauroursodeoxycholic acid inhibits the reaction [Neurotoxins results in increased activity of CASP3 protein]; tauroursodeoxycholic acid inhibits the reaction [TGFB1 protein results in increased activity of CASP3 protein]
tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in increased expression of CASP3 mRNA]; tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in increased expression of CASP3 protein]
tauroursodeoxycholic acid inhibits the reaction [Quercetin promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]]; tauroursodeoxycholic acid inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]; tauroursodeoxycholic acid inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP3 protein]; tauroursodeoxycholic acid inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]
tauroursodeoxycholic acid results in decreased activity of CASP3 protein
CTD PMID:12198651, PMID:12773247, PMID:15190125, PMID:15222754, PMID:17436368, PMID:17559149, PMID:18368144, PMID:25611565, PMID:29751043 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp4 caspase 4 multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP4 protein] CTD PMID:17559149 NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
JBrowse link
G Casp6 caspase 6 multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP6 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased activity of CASP6 protein] CTD PMID:16923170 NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967
Ensembl chr 2:235,341,365...235,353,967
JBrowse link
G Casp7 caspase 7 multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [SERPINA1 protein mutant form results in increased activity of CASP7 protein]; tauroursodeoxycholic acid inhibits the reaction [Thapsigargin results in increased activity of CASP7 protein] CTD PMID:12198651, PMID:17559149 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [Chenodeoxycholic Acid co-treated with tauroursodeoxycholic acid] results in increased activity of CASP9 protein; tauroursodeoxycholic acid inhibits the reaction [Quercetin promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]]; tauroursodeoxycholic acid inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP9 protein] CTD PMID:12773247, PMID:14976352, PMID:25611565 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Ccn2 cellular communication network factor 2 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CCN2 mRNA CTD PMID:15885361 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
EXP tauroursodeoxycholic acid inhibits the reaction [Deoxycholic Acid results in increased expression of CCND1 protein]
tauroursodeoxycholic acid results in decreased expression of CCND1 mRNA; tauroursodeoxycholic acid results in decreased expression of CCND1 protein
CTD PMID:15885361, PMID:17431217 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cdh17 cadherin 17 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CDH17 mRNA CTD PMID:15885361 NCBI chr 5:25,354,187...25,443,675
Ensembl chr 5:25,391,115...25,443,718
JBrowse link
G Cdh2 cadherin 2 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CDH2 mRNA CTD PMID:15885361 NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta increases expression EXP tauroursodeoxycholic acid results in increased expression of CEBPD mRNA CTD PMID:15885361 NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [Xylitol results in increased expression of CHAC1 protein] CTD PMID:32275922 NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425
JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CITED2 mRNA CTD PMID:15885361 NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786
JBrowse link
G Cps1 carbamoyl-phosphate synthase 1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CPS1 mRNA CTD PMID:15885361 NCBI chr 9:74,113,437...74,236,274
Ensembl chr 9:74,124,016...74,236,274
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [tauroursodeoxycholic acid results in increased phosphorylation of and results in increased activity of CREB1 protein]; calphostin C inhibits the reaction [tauroursodeoxycholic acid results in increased phosphorylation of and results in increased activity of CREB1 protein]; KN 62 inhibits the reaction [tauroursodeoxycholic acid results in increased phosphorylation of and results in increased activity of CREB1 protein]; tauroursodeoxycholic acid results in increased phosphorylation of and results in increased activity of CREB1 protein CTD PMID:15861431 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
JBrowse link
G Cs citrate synthase multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in decreased activity of CS protein]; tauroursodeoxycholic acid inhibits the reaction [N-palmitoylsphingosine results in decreased expression of CS mRNA] CTD PMID:28223344 NCBI chr 7:2,752,680...2,778,963
Ensembl chr 7:2,752,680...2,778,963
JBrowse link
G Csad cysteine sulfinic acid decarboxylase decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CSAD mRNA CTD PMID:15885361 NCBI chr 7:143,781,520...143,810,880
Ensembl chr 7:143,781,702...143,793,970
JBrowse link
G Cth cystathionine gamma-lyase decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CTH mRNA CTD PMID:15885361 NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CYP1A2 mRNA CTD PMID:15885361 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CYP27A1 mRNA CTD PMID:15885361 NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
JBrowse link
G Cyp2a2 cytochrome P450, family 2, subfamily a, polypeptide 2 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CYP2A2 mRNA CTD PMID:15885361 NCBI chr 1:83,744,229...83,766,490
Ensembl chr 1:83,653,234...83,766,484
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CYP2B3 mRNA CTD PMID:15885361 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Cyp2c12 cytochrome P450, family 2, subfamily c, polypeptide 12 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CYP2C12 mRNA CTD PMID:15885361 NCBI chr 1:258,709,726...258,766,873
Ensembl chr 1:258,709,721...258,766,881
JBrowse link
G Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CYP2F4 mRNA CTD PMID:15885361 NCBI chr 1:83,933,974...83,947,804
Ensembl chr 1:83,933,942...83,947,821
JBrowse link
G Cyp4f1 cytochrome P450, family 4, subfamily f, polypeptide 1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of CYP4F1 mRNA CTD PMID:15885361 NCBI chr 7:15,179,472...15,191,113
Ensembl chr 7:15,179,467...15,190,796
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions EXP
ISO
tauroursodeoxycholic acid inhibits the reaction [Ethanol results in increased expression of DDIT3 protein]
tauroursodeoxycholic acid inhibits the reaction [2,4-dichlorophenol results in increased expression of DDIT3 mRNA]; tauroursodeoxycholic acid inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of DDIT3 mRNA]; tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in increased expression of DDIT3 mRNA]; tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in increased expression of DDIT3 protein]; tauroursodeoxycholic acid inhibits the reaction [N-palmitoylsphingosine results in increased expression of DDIT3 mRNA]
tauroursodeoxycholic acid inhibits the reaction [Quercetin results in increased expression of DDIT3 protein]; tauroursodeoxycholic acid inhibits the reaction [ursolic acid results in increased expression of DDIT3 protein]
CTD PMID:23544086, PMID:24802810, PMID:25611565, PMID:27853103, PMID:28223344, PMID:29751043 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dpp4 dipeptidylpeptidase 4 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of DPP4 mRNA CTD PMID:15885361 NCBI chr 3:48,291,055...48,372,672
Ensembl chr 3:48,291,055...48,372,672
JBrowse link
G E2f1 E2F transcription factor 1 increases expression
decreases expression
EXP tauroursodeoxycholic acid results in increased expression of E2F1 mRNA
tauroursodeoxycholic acid results in decreased expression of E2F1 protein
CTD PMID:15255934 NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
JBrowse link
G Edn1 endothelin 1 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of EDN1 protein CTD PMID:15556138 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [Nicotine results in increased phosphorylation of EIF2AK3 protein] CTD PMID:26803847 NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [Quercetin results in increased phosphorylation of EIF2S1 protein]; tauroursodeoxycholic acid inhibits the reaction [ursolic acid results in increased phosphorylation of EIF2S1 protein] CTD PMID:24802810, PMID:25611565 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of ENPP1 mRNA CTD PMID:15885361 NCBI chr 1:21,748,201...21,813,205
Ensembl chr 1:21,748,261...21,813,371
JBrowse link
G Ergic3 ERGIC and golgi 3 multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [Tunicamycin results in decreased expression of ERGIC3 protein] CTD PMID:27588471 NCBI chr 3:151,553,567...151,563,318
Ensembl chr 3:151,553,578...151,563,364
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein] CTD PMID:29031535 NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
JBrowse link
G Esrrg estrogen-related receptor gamma multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [Dronabinol results in increased expression of ESRRG mRNA] CTD PMID:31054322 NCBI chr13:106,063,799...106,683,353
Ensembl chr13:106,463,368...106,683,436
JBrowse link
G Fabp4 fatty acid binding protein 4 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of FABP4 mRNA CTD PMID:24312631 NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
JBrowse link
G Fads1 fatty acid desaturase 1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of FADS1 mRNA CTD PMID:15885361 NCBI chr 1:226,234,034...226,249,118
Ensembl chr 1:226,234,074...226,249,138
JBrowse link
G Fads3 fatty acid desaturase 3 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of FADS3 mRNA CTD PMID:15885361 NCBI chr 1:226,091,774...226,108,332
Ensembl chr 1:226,091,774...226,108,332
JBrowse link
G Fah fumarylacetoacetate hydrolase decreases expression EXP tauroursodeoxycholic acid results in decreased expression of FAH mRNA CTD PMID:15885361 NCBI chr 1:146,713,663...146,736,339
Ensembl chr 1:146,713,676...146,736,261
JBrowse link
G Fas Fas cell surface death receptor decreases expression EXP tauroursodeoxycholic acid results in decreased expression of FAS mRNA CTD PMID:14623915 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [Dronabinol results in increased expression of FLT1 mRNA] CTD PMID:31054322 NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
JBrowse link
G Fmo3 flavin containing dimethylaniline monoxygenase 3 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of FMO3 mRNA CTD PMID:15885361 NCBI chr13:80,837,418...80,856,214
Ensembl chr13:80,837,420...80,862,963
JBrowse link
G Fn1 fibronectin 1 decreases expression
multiple interactions
EXP tauroursodeoxycholic acid results in decreased expression of FN1 mRNA
tauroursodeoxycholic acid inhibits the reaction [AGT protein results in increased expression of FN1 protein]
CTD PMID:15885361, PMID:25398788 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [Taurolithocholic Acid results in increased expression of FOS mRNA] CTD PMID:18164257 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Foxo1 forkhead box O1 multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [Ethanol results in decreased acetylation of FOXO1 protein] CTD PMID:23544086 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
JBrowse link
G Ftcd formimidoyltransferase cyclodeaminase decreases expression EXP tauroursodeoxycholic acid results in decreased expression of FTCD mRNA CTD PMID:15885361 NCBI chr20:12,806,957...12,820,466
Ensembl chr20:12,806,957...12,820,466
JBrowse link
G G6pc glucose-6-phosphatase, catalytic subunit multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [Ethanol results in increased expression of G6PC mRNA]; tauroursodeoxycholic acid inhibits the reaction [Ethanol results in increased expression of G6PC protein] CTD PMID:23544086 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
JBrowse link
G Gamt guanidinoacetate N-methyltransferase decreases expression EXP tauroursodeoxycholic acid results in decreased expression of GAMT mRNA CTD PMID:15885361 NCBI chr 7:12,314,848...12,317,998
Ensembl chr 7:12,314,848...12,317,998
JBrowse link
G Gckr glucokinase regulator decreases expression EXP tauroursodeoxycholic acid results in decreased expression of GCKR mRNA CTD PMID:15885361 NCBI chr 6:26,355,296...26,385,761
Ensembl chr 6:26,355,296...26,385,761
JBrowse link
G Glud1 glutamate dehydrogenase 1 decreases expression EXP tauroursodeoxycholic acid results in decreased expression of GLUD1 mRNA